3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
3
Withdrawn
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Neoplasm, Residual
1
Leukemia, Myeloid, Acute
1
Interventions
Cytarabine
25
Azacitidine
17
fludarabine phosphate
15
fludarabine
15
Cyclophosphamide
14
venetoclax
8
Peripheral Blood Stem Cell Transplantation
8
Methotrexate
8
Busulfan
8
Granulocyte Colony-Stimulating Factor
7
Filgrastim
7
Whole-Body Irradiation
6
Decitabine
6
Cyclosporine
6
Injections
5
Idarubicin
5
decitabine and cedazuridine drug combination
4
Tacrolimus
4
Radiotherapy
4
Mycophenolic Acid
4
Mitoxantrone
4
Daunorubicin
4
Cladribine
4
CPX-351
4
Biopsy
4
midostaurin
3
merphos
3
magrolimab
3
gilteritinib
3
Stem Cell Transplantation
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Leukemia, Myeloid, Acute
×
siremadlin
×
Clear all
NCT03760445
2020-01-09
HDM201 Added to CT in R/R or Newly Diagnosed AML
Novartis
Phase 1/2
Withdrawn